Since the lowering of the cut-off value for hormone receptor positive breast cancers by the ASCO/CAP in 2010, repeated concerns were raised that the outcome of patients with LowHR tumors is worse, as they do not benefit from endocrine therapy. Here, NR4A1 is linked to breast carcinoma.